I found a website describing that trial, but not much other information. A pharmasutical company is appying for a patent, and the owner is a co-author on some published research on Natura-a and prostate cancer. (Longgui Wang/President, Natrogen Therapeutics International, Inc)
I did get into some medical literature, and read a paper on Natura-a for rheumatoid arthritis. They gave a fairly accessible description of what the drug is and how it seems to work. It appears to regulate the IL-17 cytokine in the immune system, which is related to Th-17 helper cells, and inflammatory responses
"Natura-a, a newly developed cytokine regulator, has been
shown to have potent therapeutic activities against dextran
sulfate sodium salt-induced chronic ulcerative colitis in Balb/c
Mice. This molecule is capable of rebalancing expression/
production of various cytokines, i.e. inhibiting expression of
pro-inflammatory cytokines, TNF-a, IL-1b, IL-6 and simultaneously
stimulating regulatory cytokine IL-10 in LPS-stimulated
THP1 human monocytes and inhibit STAT3 phosphorylation
(unpublished data; US patents pending)."
"Natura-a is a cytokine regulator being developed by Natrogen
Therapeutics International (NY, USA). It is small synthetic
molecule, and chemically belongs to dihydroindole family with
a molecular weight 276 and a melting point of 235–237 C1. The
chemical name of Natura-a is N-methyl-D3, 30-dihydroindole-2,
20 diketone. Experiments demonstrate that Natura-a significantly
inhibits expression of various pro-inflammatory cytokines including
IL-1b, IL-6 and TNF-a while stimulates expression of the
regulatory cytokine IL-10 in LPS-stimulated THP-1 cells (Study
NTI-2001 Report, Supporting Information support S1). Natura-a
also shows efficacy against acute and chronic ulcerative colitis in
dextran sulfate sodium salt induced mouse models (Manuscript
in Preparation)." [I checked, this article has still not come out]
"Our results showed that Natura-a has a strong effect on Th-1
and Th-17 differentiation. Recent papers show that CIA is
governed by two proinflammatory CD4 T-cell types called Th-1
and Th-17 cells. These cells are mainly producers of IFN-g and
IL-17A and these syntheses are induced by distinct cytokines in the
medium; IL-12 for Th-1 and IL6, TGF-b for Th-17 cells."
-----------------
This stuff is hard for me to read, but the goal seems to be to re-balance the immune system, so it would be sort of like a cure if it works in humans.
From this trial's publication, to toxicity studies, to FDA approval, to appearing on the shelf .... would likely still be 3-5 years in my opinion.